scholarly journals Response to different medical treatment options for mastalgia in fibrocystic breast disease

2021 ◽  
Vol 12 (1) ◽  
pp. 22-29
Author(s):  
Samia Mostary ◽  
Md Manir Hossain Khan ◽  
Md A Mottalab Hossain ◽  
Tapash Kumar Maitra
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Pharmacological Treatment ◽  
Medical Management ◽  
Breast Disease ◽  
Management Options ◽  
Evening Primrose ◽  
Fibrocystic Breast Disease

Background: Fibrocystic breast disease is the most common type of benign breast disease and mastalgia is the most common symptom of fibrocystic breast disease. Various types of medical management are given as a gold standard treatment for that. The aim of this study was to compare the effects of different commonly used medical management options of mastalgia of fibrocystic breast disease on the quality of life of patients and their side effects as well. Methods: This quasi-experimental study was carried out in Out-patients Department of General Surgery, BIRDEM General Hospital, Dhaka, from July 2018 to June 2019. Total 45 patients with fibrocystic breast disease were selected according to the eligibility criteria and were allocated to two groups by alternative random selection. In non-pharmacological treatments receiving group, lifestyle modification advices along with evening primrose oil were given. On the other hand, in pharmacological treatment receiving group, bromocriptine and danazole were given according to some selection criteria of the patients. Response of treatments to each group and side effects were determined at one month, three months and six months follow-up respectively. Mastalgia was measured by visual analogue scale (VAS) score and quality of life was calculated by modified WHO-QOL scoring in each follow-up. Results: Patients had an average age of 30.24±6.93 years with a majority in the age group 31-35 years (33.3%). Most patients were married (64.4%), housewives (62.20%), from middle-class groups (62.20%), multiparous (57.78%) and the majority had absence of the family history of breast diseases (84.45%). Majority of them presented with cyclical mastalgia (57.78%), bilateral mastalgia (60%) and mastalgia with lumpiness (44.4%). Among the patients who received non-pharmacological treatment, mastalgia improved in 34.78% cases and patients received pharmacological treatment, mastalgia improved in 72.73% cases. Different domains of quality of life were improved significantly in patients who received pharmacological treatment. Though majority of the patients had side effects due to pharmacological treatment, they were well tolerated. Conclusion: Despite having various side effects, pharmacological management by danazol or bromocriptine was well tolerated to our patients and a dramatic improvement was observed on quality of life than the nonpharmacologically treated patients. BIRDEM Med J 2022; 12(1): 22-29

scholarly journals Clinical Response to Different Medical Treatment Options for Mastalgia in Fibrocystic Breast Disease among Women at a Tertiary Care Hospital in Dhaka City

2021 ◽  
Vol 8 (2) ◽  
pp. 95-99
Author(s):  
Samia Mostary ◽  
Md Manir Hossain Khan ◽  
Md A Mottalab Hossain ◽  
Tapash Kumar Maitra
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Pharmacological Treatment ◽  
Medical Management ◽  
Breast Disease ◽  
Care Hospital ◽  
Evening Primrose ◽  
Fibrocystic Breast Disease ◽  
Prospective Longitudinal

Background: Various types of medical management are given for mastalgia in fibrocystic breast disease. Objective: The aim of this study was to compare the effects of different commonly used medical management options of mastalgia of fibrocystic breast disease on the quality of life of the respondents and their side effects as well. Methods: This prospective longitudinal study was carried out in Out-patients Department of General Surgery, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM) General Hospital, Dhaka, Bangladesh from July 2018 to June 2019. The patients with fibrocystic breast disease were selected according to the eligibility criteria and are allocated to two groups by alternative random selection. In non-pharmacological treatments receiving group, lifestyle modification advices along with Evening Primrose Oil were given. On the other hand, in pharmacological treatment receiving group, Bromocriptine and Danazole were given according to some selection criteria of the patients. Response of treatments to each group & side effects were determined at one month, three months and six months follow up respectively. Results: A total number of 45 patients were recruited for this study. Majority of them presented with cyclical mastalgia (57.78%), bilateral mastalgia (60%) and mastalgia with lumpiness (44.4%). Among the patients who received non- pharmacological treatment, mastalgia improved in 34.78% cases and patients received pharmacological treatment, mastalgia improved in 72.73% cases. Different domains of quality of life were improved significantly in patients who received pharmacological treatment. Conclusion: In conclusion pharmacological management by Danazol or Bromocriptine has well tolerated to the patients. Journal of Current and Advance Medical Research, July 2021;8(2):95-99

scholarly journals The impact of hyperbaric oxygen therapy on late radiation toxicity and quality of life in breast cancer patients

2021 ◽  
Author(s):  
Marilot C. T. Batenburg ◽  
Wies Maarse ◽  
Femke van der Leij ◽  
Inge O. Baas ◽  
Onno Boonstra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Side Effects ◽  
Cancer Patients ◽  
Oxygen Therapy ◽  
Radiation Toxicity ◽  
Breast Pain ◽  
Breast Cancer Patients

Abstract Purpose To evaluate symptoms of late radiation toxicity, side effects, and quality of life in breast cancer patients treated with hyperbaric oxygen therapy (HBOT). Methods For this cohort study breast cancer patients treated with HBOT in 5 Dutch facilities were eligible for inclusion. Breast cancer patients with late radiation toxicity treated with ≥ 20 HBOT sessions from 2015 to 2019 were included. Breast and arm symptoms, pain, and quality of life were assessed by means of the EORTC QLQ-C30 and -BR23 before, immediately after, and 3 months after HBOT on a scale of 0–100. Determinants associated with persistent breast pain after HBOT were assessed. Results 1005/1280 patients were included for analysis. Pain scores decreased significantly from 43.4 before HBOT to 29.7 after 3 months (p < 0.001). Breast symptoms decreased significantly from 44.6 at baseline to 28.9 at 3 months follow-up (p < 0.001) and arm symptoms decreased significantly from 38.2 at baseline to 27.4 at 3 months follow-up (p < 0.001). All quality of life domains improved at the end of HBOT and after 3 months follow-up in comparison to baseline scores. Most prevalent side effects of HBOT were myopia (any grade, n = 576, 57.3%) and mild barotrauma (n = 179, 17.8%). Moderate/severe side effects were reported in 3.2% (n = 32) of the patients. Active smoking during HBOT and shorter time (i.e., median 17.5 vs. 22.0 months) since radiotherapy were associated with persistent breast pain after HBOT. Conclusion Breast cancer patients with late radiation toxicity reported reduced pain, breast and arm symptoms, and improved quality of life following treatment with HBOT.

A prospective follow-up of quality of life, wellbeing, side effects and compliance in the treatment of first episode psychosis

2003 ◽  
Vol 60 (1) ◽  
pp. 329
Author(s):  
T. Taylor ◽  
M. O'Toole ◽  
J. Walters ◽  
R. Ohlsen ◽  
R. Purvis ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
First Episode Psychosis ◽  
First Episode ◽  
Episode Psychosis

scholarly journals A Novel Digital Patient-Reported Outcome Platform for Head and Neck Oncology Patients–-A Pilot Study

2016 ◽  
Vol 9 ◽  
pp. CMENT.S40219 ◽  
Author(s):  
Maria K. Peltola ◽  
Joel S. Lehikoinen ◽  
Lauri T. Sippola ◽  
Kauko Saarilahti ◽  
Antti A. Mäkitie
Keyword(s):  
Quality Of Life ◽  
Pilot Study ◽  
Side Effects ◽  
Head And Neck ◽  
Cancer Patients ◽  
Early Stage ◽  
Patient Reported Outcome ◽  
Patient Reported

Introduction The patient's role in toxicity reporting is increasingly acknowledged. There is also a need for developing modern communication methods between the patient and the medical personnel. Furthermore, the increasing number of head and neck cancer (HNC) patients is reflected in the volume of treatment follow-up visits, which remains a challenge for the health care. Electronic patient-reported outcome (ePRO) measures may provide a cost-efficient way to organize follow-up for cancer patients. Materials and Methods We tested a novel ePRO application called Kaiku®, which enables real-time, online collection of patient-reported outcomes, such as side effects caused by treatment and quality of life. We conducted a pilot study to assess the suitability of Kaiku® for HNC patients at the Department of Oncology, Helsinki University Hospital, Helsinki, Finland. Patients used Kaiku® during and one month after radiotherapy to report treatment-related side effects and quality of life. Two physicians and a nurse performed the practical electronic communication part of the study. Results Five of the nine patients agreed to participate in the study: three of them had local early-stage larynx cancer (T2N0, T1aN0, and T2N0) and the remaining two patients had early-stage base of tongue cancer (T2N0 and T1N2b). The degree of side effects reported by the patients via Kaiku® ranged from mild to life threatening. The number of outcome data points on patients' progress was significantly increased, which resulted in a better follow-up and improved communication between the patient and the care team. Conclusions Kaiku® seems to be a suitable tool to monitor side effects and quality of life during and after radiotherapy among HNC patients. Kaiku® and similar tools could be useful in organizing a cost-effective follow-up process for HNC patients. We recommend conducting a larger study to further assess the impact of an ePRO solution in routine clinical practice. • ePRO solutions may aid in the follow-up for cancer patients. • They seem suitable to monitor, for example, side effects and quality of life. • These systems ensure fast patient-driven reporting.

Effect of video-based patient education on pancreatic cancer knowledge and behavior.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 11005-11005
Author(s):  
Wendy Turell ◽  
Tariqa Ackbarali ◽  
Eileen Mary O'Reilly ◽  
Matthew Alsante ◽  
Kathryn Pucci ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pancreatic Cancer ◽  
Patient Education ◽  
Medical Management ◽  
Psychosocial Support ◽  
Lessons Learned ◽  
Basic Knowledge ◽  
And Behavior

11005 Background: Treatment outcomes for pancreatic cancer are optimized when patients/caregivers are engaged, informed and supported participants in their care. However, challenges exist regarding care engagement, disease and treatment related education, and the attainment of adequate psychosocial support. To address these needs, we created video-based patient education activities with the National Pancreas Foundation to empower patients/care with information and resources on pancreatic cancer facts, diagnosis, medical management, and strategies to minimize side effects and maximize quality of life. Methods: One 1-hour patient education activity was broadcast live and online, followed by on-demand release, in 2018-2019 at CancerCoachLive.com and via Facebook Video for 12 months. Features included panel discussions, slides, live polling and Q&A, and video vignettes of real patient experiences. Knowledge-focused test questions were administered at 3 time points (pre-activity, immediate post-activity, and 2-mos [follow-up] post). Behavioral and communication-focused questions were also asked at follow-up. Data from these questions, live poll responses, and learner-submitted questions pre-event and during live Q&A were analyzed to determine engagement, lessons learned and continuing patient needs. Results: In total, 6,276 patients took part in the activity. Patient questions prior to and during the activity focused on basic knowledge about pancreas gland function, tumor development, disease escalation, and medical management. In-session polling results revealed that prognosis and life expectancy were the top concerns for participants. Two months post-education evaluation showed: 33% reported improved communication with their healthcare providers (HCPs) regarding pancreatic cancer; 46% reported improved feelings of being more “in-control” of health care decisions; 25% reported improved care behaviors for their health. Reports of improved HCP communication were specific to: side effect management, clinical trials availability, treatment option knowledge, and confidence related to engaging in discussions. Knowledge improvements were observed for 3 of 4 questions related to facts about the pancreas, pancreatic cancer, and treatment.Conclusions: Patient/caregiver education on pancreatic cancer yields gains in knowledge and behavior, improves patient/caregiver engagement, improves treatment decision-making, and maximizes quality of life.

Drugs Treatment for Deaf People

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
C. Moreno Menguiano
Keyword(s):  
Quality Of Life ◽  
Mental Health ◽  
Side Effects ◽  
Pharmacological Treatment ◽  
Daily Life ◽  
Psychoactive Drugs ◽  
Deaf People ◽  
Deaf Persons ◽  
The Way

The resources for deaf persons’ mental health and the studies in the field of the psychopharmacology are nowadays inadequate to meet the specific needs of this population. The indications or the way of using the medication do not differ between deaf and hearing persons, but it is not well-known among professionals that during the psychopharmacologic treatment of deaf patients it is possible to observe the presence of intense and unexpected side effects of the medication, so that it does turn out to be indispensable to give special attention to the prescription of psychoactive drugs in deaf persons. This ignorance is partly due to the fact that the research in this area is deficient. The above mentioned side effects are more prevailing and intense in deaf persons than in hearings and often interfere with basic aspects of a person's daily life as it is his system of communication, the language of signs that becomes affected, for example, due to alterations in the vision or the movement, which means in practice (at the same time) a decrease in the quality of life. Therefore, our aim is to emphasize that the indications for pharmacological treatment in deaf persons are the same than in hearings and at the same time to emphasize the importance of knowing the specific needs.

scholarly journals Improving of Cognition and Quality of Life in Schizophrenia With One-month and Three-month Paliperidone Palmitate Treatment

2021 ◽  
Author(s):  
Chen-Lin Chang ◽  
Yong-Chen Huang ◽  
Pinchen Yang ◽  
For-Wey Lung
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Total Cholesterol ◽  
Social Performance ◽  
Paliperidone Palmitate ◽  
Social Functions ◽  
Future Studies ◽  
Cholesterol Levels

Abstract An antipsychotic drug, Paliperidone palmitate (PDP), is administered to schizophrenics as injections at one-month (Sustenna) or three-month (Trinza) intervals. The present study was a series of clinical trial study, which included two sub-study, sought to compare the effects of treatment, social function, and side effects between two treatments in schizophrenics. In Study 1, total of 42 participants were received the Sustenna treatment for three months. In Study 2, total of 72 participants were recruited for Trinza treatment. The results showed Personal and Social Performance scales (PSP) significantly increased over time with both two treatments. Total cholesterol levels significantly decreased with Sustenna, which negatively influenced the cognitive functions, and the quality of life. UKU scales significantly decreased with Trinza after 15 months. In Brief, schizophrenics receiving PDP treatment presented improvements in their cognitive and social functions over the time, whether with the Sustenna or Trinza treatment. Total cholesterol and waist circumference decreased, and the LDL/HDL ratios increased over the time after PDP treatment. Furthermore, patients receiving Trinza treatment experienced decreased side effects. Nonetheless, schizophrenics had a significantly better quality of life after both Sustenna and Trinza treatment. Future studies should be consider larger samples and longer follow up.

scholarly journals Effect of a Mobile App for the Pharmacotherapeutic Follow-Up of Patients With Cancer on Their Health Outcomes: Quasi-Experimental Study (Preprint)

2020 ◽  
Author(s):  
Roberto Collado-Borrell ◽  
Vicente Escudero-Vilaplana ◽  
Almudena Ribed ◽  
Cristina Gonzalez-Anleo ◽  
Maite Martin-Conde ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Health Outcomes ◽  
Intervention Group ◽  
Mobile App ◽  
Control Group ◽  
Adherence To Treatment ◽  
Quasi Experimental

BACKGROUND Oral antineoplastic agents (OAAs) have revolutionized cancer management. However, they have been reported with adverse side effects and drug-drug interactions. Moreover, patient adherence to OAA treatment is critical. Mobile apps can enable remote and real-time pharmacotherapeutic monitoring of patients, while also promoting patient autonomy in their health care. OBJECTIVE The primary objective was to analyze the effect of using a mobile app for the follow-up of patients with oncohematological malignancies undergoing treatment with OAAs on their health outcomes. The secondary objectives were to analyze the role of the app in communication with health care professionals and patient satisfaction with the app. METHODS We performed a comparative, quasi-experimental study based on a prepost intervention with 101 patients (control group, n=51, traditional pharmacotherapeutic follow-up vs intervention group, n=50, follow-up through e-OncoSalud, a custom-designed app that promotes follow-up at home and the safety of patients receiving OAAs). The effect of this app on drug safety, adherence to treatment, and quality of life was evaluated. RESULTS With regard to drug safety, 73% (37/51) of the patients in the control group and 70% (35/50) of the patients in the intervention group (<i>P</i>=.01) presented with drug-related problems. The probability of detecting an insufficiently treated health problem in the intervention group was significantly higher than that in the control group (<i>P</i>=.04). The proportion of patients who presented with side effects in the intervention group was significantly lower than that in the control group (<i>P</i>&gt;.99). In the control group, 49% (25/51) of the patients consumed some health resources during the first 6 months of treatment compared with 36% (18/50) of the patients in the intervention group (<i>P</i>=.76). Adherence to treatment was 97.6% (SD 7.9) in the intervention group, which was significantly higher than that in the control group (92.9% [SD 10.0]; <i>P</i>=.02). The EuroQol-5D in the intervention group yielded a mean (SD) index of 0.875 (0.156), which was significantly higher than that in the control group (0.741 [0.177]; <i>P</i>&lt;.001). Approximately 60% (29/50) of the patients used the messaging module to communicate with pharmacists. The most frequent types of messages were acknowledgments (77/283, 27.2%), doubts about contraindications and interactions with OAAs (70/283, 24.7%), and consultations for adverse reactions to treatment (39/283, 13.8%). The satisfaction with the app survey conducted in the intervention group yielded an overall mean (SD) score of 9.1 (0.4) out of 10. CONCLUSIONS Use of e-OncoSalud for the real-time follow-up of patients receiving OAAs facilitated the optimization of some health outcomes. The intervention group had significantly higher health-related quality of life and adherence to treatment than the control group. Further, the probability of the intervention group presenting with side effects was significantly lower than that of the control group.

Sign in / Sign up

Export Citation Format

Share Document